Oxford Biomedica (LON:OXB) Announces Quarterly Earnings Results

Key Points

• Oxford Biomedica reported 2025 revenue up 33% to £170.9m and its first full‑year operating EBITDA profit of £8.1m, and guided 2026 revenue of £220–240m with an expected ~10% full‑year operating EBITDA margin (H1 loss anticipated for integration and tech transfers).
• Commercial visibility improved sharply with backlog up 36% to £204m and contracted client orders of £224m (covering ~60% of 2026 guidance and >80% including risk‑adjusted pipeline), while the acquisition of an FDA‑approved Durham facility provides an end‑to‑end U.S. manufacturing footprint to accelerate deals and late‑stage launches.
• Balance sheet and market context: year‑end cash of £96.9m and net cash ~£55.4m plus a £60m placing and new Oaktree facility give funding flexibility, although shares fell ~5.8% to GBX 571 amid largely bullish analyst coverage (average target ~GBX 687).

Oxford Biomedica (LON:OXB - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported GBX (26.92) EPS for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative return on equity of 82.57% and a negative net margin of 24.51%.

Here are the key takeaways from Oxford Biomedica's conference call:

• OXB reported strong 2025 results with revenue up 33% to £170.9m and its first full-year operating EBITDA profit of £8.1m since the strategic refocus.
• The company says its commercial visibility is robust, with backlog up 36% to £204m and contracted client orders at £224m, covering ~60% of 2026 guidance and >80% when including risk‑adjusted pipeline items.
• OXB completed the acquisition of an FDA‑approved commercial-scale Durham facility, giving it an end‑to‑end U.S. manufacturing footprint that management says accelerated commercial deals (e.g., BMS) and expands capacity for late‑stage launches.
• 2026 guidance is for £220–240m revenue and ~10% full‑year operating EBITDA margin (H1 expected EBITDA‑lossy due to maintenance, tech transfers and Durham integration), with capex ~£50m for 2026–27 and medium‑term targets of 25–30% y/y growth and ≥20% EBITDA in 2027.
• Balance sheet strengthened with year‑end cash of £96.9m, net cash ~£55.4m, a £60m equity placing and a new Oaktree facility, which management says provides funding flexibility for network investment and ramp‑up.

Oxford Biomedica Trading Down 5.8%

Oxford Biomedica stock traded down GBX 35 during mid-day trading on Thursday, hitting GBX 571. 487,453 shares of the company's stock were exchanged, compared to its average volume of 601,280. The company's 50 day simple moving average is GBX 747.49 and its 200-day simple moving average is GBX 665.24. The company has a quick ratio of 1.67, a current ratio of 1.89 and a debt-to-equity ratio of 322.11. The firm has a market capitalization of £690.18 million, a P/E ratio of -15.76 and a beta of 1.04. Oxford Biomedica has a fifty-two week low of GBX 232.50 and a fifty-two week high of GBX 952.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on OXB. Jefferies Financial Group started coverage on Oxford Biomedica in a research note on Monday. They issued a "buy" rating and a GBX 827 target price on the stock. Deutsche Bank Aktiengesellschaft boosted their target price on Oxford Biomedica from GBX 735 to GBX 800 and gave the stock a "buy" rating in a research report on Friday, January 9th. Finally, Stifel Nicolaus reiterated a "buy" rating and issued a GBX 950 price target on shares of Oxford Biomedica in a research report on Wednesday, March 11th. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of GBX 687.

Oxford Biomedica Company Profile

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.